M-Vax: an autologous, hapten-modified vaccine for human cancer

Bibliography

• MULLEN CA, URBAN JL, VAN WAES C,ROWLEY DA, SCHREIBER H: Multiple Cancers. Tumor burden permits the outgrowth of other cancers. J. Erp. Med. (1985) 162:1665–1682.
   Google Scholar
• BERD D, MAGUIRE HC JR., MASTRANGELO MJ: Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. (1986) 46:2572–2577.
   Google Scholar
• WEIGLE WO: The production of thyroiditisand antibody following injection of unaltered thyroglobulin without adjuvant into rabbits previously stimulated with altered thyroglobulin. J. Exp. Med. (1965) 122:1049–1062.
   PubMed Web of Science ®Google Scholar
• MARTINS, WELTZIEN HU: T cell recognition of haptens, a molecular view. Int. Arch. Allergy ImmurroL (1994) 104:10–16.
   PubMed Web of Science ®Google Scholar
• MILLER SD, CLAMAN HN: The induction of hapten-specific T cell tolerance by using hapten-modified lymphoid cells. I. Characteristics of tolerance induction. 1. Inamurrol. (1976) 117:1519–1526.
   Google Scholar
• BERD D, MURPHY G, MAGUIRE HC JR, MASTRANGELO MJ: Immunization with haptenized, autologous tumor cells induces inflammation of human melanoma metastases. Cancer Res. (1991) 51:2731–2734.
   PubMed Web of Science ®Google Scholar
• BERD D, MAGUIRE HC JR., MASTRANGELO MJ, MURPHY GF: Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Inamurrol. Irnmunother. (1994) 39:141–147.
   Google Scholar
• LATTIME EC, MASTRANGELO MJ, BAGASRA O, LI W BERD D: Expression of cytokine mRNA in human melanoma tissues. Cancer Immurrol. Irnmunother. (1995) 41:151–156.
   PubMed Web of Science ®Google Scholar
• SENSI ML, FARINA C, MACCALLI C etal.: Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. 1 Clin. Invest. (1997) 99:710–717.
   Google Scholar
• BERD D, SATOT, COHN H, MAGUIRE HC JR., MASTRANGELO MJ: Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: Regression of pulmonary metastases. Internat. 1 Cancer (2001) 94:531–539.
   Google Scholar
• BERD D, MAGUIRE HC JR., SCHUCHTER LM et al: Autologous, hapten-modified melanoma vaccine as post- surgical adjuvant treatment after resection of nodal metastases. 1. Clirr. arca (1997) 15:2359–2370.
   Google Scholar
• COIT DG, ROGATKO A, BRENNAN MF:Prognostic factors in patients with melanoma metastatic to axillary or inguinal lymph nodes: A multivariate analysis. Ann. Sorg. (1991) 214:627–636.
   PubMed Web of Science ®Google Scholar
• BALCH CM, SOONG S-J, GERSHENWALD JE, MORABITO A et al: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system...J. Cl/n. arca (2001) 19:3622–3634.
   PubMed Web of Science ®Google Scholar
• KIRKWOOD JM, STRAWDERMAN MH, ERNSTOFF MS, SMITH TJ, BORDEN EC, BLUM RH: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684.1 Cl/n. Chico' (1996) 14:7–17.
   Google Scholar
• KIRKWOOD JM, IBRAHIM JG, SOSMANJA etal.: High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of intergroup trial E1694/ 59512/C509801.1 Clirr. arca (2001) 19:2370–2380.
   Google Scholar
• BERD D, MASTRANGELO MJ, SATO T, BLOOME E: Effectiveness of autologous, hapten-modified melanoma vaccine depends on the timing of an induction dose. Proc. Am. Assoc. Cancer Res. (2001) 42:683.
   Google Scholar
• LIVINGSTON PO, NATOLI EJ, CALVESMJ, STOCKERT E, OETTGEN HE OLD LJ: Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients. Proc Natl. Acad. Li. USA (1987) 84:2911–2915.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, SCHWARTZENTRUBER DJ etal.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma Nat. Med. (1998) 4:321-327. See comments.
   Google Scholar
• MARCHAND M, VAN BAREN N, WEYNANTS P et al.: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-Al. Int. I Cancer (1999) 80:219–230.
   PubMed Web of Science ®Google Scholar
• LEE P WANG F, KUNIYOSHI J etal.: Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Cl/n. arca (2001) 19:3836–3847.
   Google Scholar
• STEINMAN RIVI, KAPLAN G, WITMER MD, COHN ZA: Identification of a novel cell type in peripheral lymphoid organs of mice.V. Purification of spleen dendritic cells, new surface markers, and maintenance in vitro. I Exp. Med. (1979) 149:1–16.
   Google Scholar
• MORSE MA, ZHOU LJ, TEDDER TF, LYERLY HK, SMITH C: Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleultin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. Ann. Sorg. (1997) 226:6-16. See comments.
   Google Scholar
• NESTLE FO, ALIJACIC S, GILLIET M eta/.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. (1998) 4:328–332.
   Google Scholar
• MULE JJ: Dendritic cells: at the clinical crossroads. 1. Clio. Invest. (2000) 105:707-708. Letter, comment.
   Google Scholar
• TAMURA Y, PENG P, DAOU M, SRIVASTAVA PK: Immunotherapy of tumors with autologous tumor-derived heat shock protein preparations. Science (1997) 278:117–120.
   PubMed Web of Science ®Google Scholar
• JANETZKI S, PALLA D, ROSENHAUER V, LOCHS H, LEWIS JJ, SRIVASTAVA PK: Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations: A pilot study. Lot. I Cancer (2000) 88:232–238.
   PubMed Web of Science ®Google Scholar
• VERMORKEN JB, CLAESSEN AME, VAN TINTEREN H etal.: Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 353:345–350.
   Google Scholar
• LEONG SPL, ENDERS-ZOHR E ZHOU Y-M etal.: Recombinant human granulocyte macrophage-colony stimulating factor and autologous melanoma vaccine mediate tumor regression in patients with metastatic melanoma 1. Immunother (1998) 22:166–174.
   Google Scholar
• BERD D, CARLSON J, BLOOME E, MEDLEY W, DUNTON C: Induction of delayed-type hypersensitivity to ovarian cancer cells after treatment with an autologous, hapten-modified vaccine. Proc Am. Assoc Cancer Res. (1998) 39:356. Abstract 2431.
   Google Scholar